Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
| Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
|---|---|---|---|---|
| James DeMesa | M | 66 |
MIGENIX, Inc.
 MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 7 Jahre |
| Bruce A. Schmidt | M | 68 |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 Jahre |
| AnnKatrin Petersen-Jappelli | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 4 Jahre |
| Steven Gillis | M | 71 |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 12 Jahre |
| Walter Moos | M | 69 |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 4 Jahre |
| Colin R. Mallet | M | 80 |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 13 Jahre |
| Michael Jeffrey Abrams | M | 68 |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 Jahre |
| Doug Johnson | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 Jahre |
| Francis David Duke Scott | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 8 Jahre |
| Alistair Duncan | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 6 Jahre |
| William D. Milligan | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 7 Jahre |
| A. Neil Howell | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | - |
| Richard Winston DeVries | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | - |
| W. Keith Schilit | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | - |
| Andrew J. Rae | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 Jahre |
| Pieter Dorsman | M | - |
MIGENIX, Inc.
MIGENIX, Inc. Pharmaceuticals: MajorHealth Technology MIGENIX, Inc. develops pharmaceutical drugs. It focuses on advancing therapy, improving health, and enriching life by developing and commercializing drugs in the areas of infectious and degenerative diseases. The Company's clinical programs include drug candidates for the treatment of chronic hepatitis C (Phase II), the prevention of catheter-related infections (Phase III), the treatment of neurodegenerative diseases (Phase I/II) and the treatment of acne (Phase II). MIGENIX was founded in 1993 and is headquartered in Vancouver, Canada. | 2 Jahre |
Statistik
| Land | Beziehungen | % des Gesamten |
|---|---|---|
| Kanada | 16 | 100,00% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Jacob J. Clement
- Persönliches Netzwerk
